A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars
Authors:
- Gilbert ZakineGZGilbert Zakine
- Anne Perruisseau-CarrierAPAnne Perruisseau-Carrier
- Corinne BeckerCBCorinne Becker
- Frédéric SedelFSFrédéric Sedel
- Luc TéotLTLuc Téot
- Denis BarritaultDBDenis Barritault
Open Access
- 11 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 5, ojad031
Abstract
CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue healing by stabilizing matrix proteins and protecting heparin-binding growth factors. In humans, an open self-controlled study suggested that the topical application of CACIPLIQ20 optimizes skin healing following surgery. To expand previous findings using a different CACIPLIQ20 administration regimen. Twenty-four females were referred for breast-reduction surgery. Each patient had their own control with 1 CACIPLIQ20-treated and 1 saline-treated control breast. The treated side (right or left) was randomly assigned by the operating surgeon. Scar appearance was assessed by 6 independent raters using a global visual scar comparison scale based on scar photographs. All raters were blinded toward the CACIPLIQ20-treated side. The follow-up period following surgery ranged from 1 to 12 months with a median follow-up of 6 months. Overall, there was a mean improvement of 15.2% (SD = 26.7) in favor of CACIPLIQ20 (P = .016). On the CACIPLIQ20-treated side, the mean score per patient was above 20% in 11 patients and above 30% improvement in 8 cases. In contrast, only 3 patients were considered improved by at least 20% on the control side and only 1 above 30%. A comparison of different application regimens suggested that the best trend was obtained with a single administration of CACIPLIQ20 at Day 0. In conclusion, CACIPLIQ20 could represent an interesting scar prophylactic therapy, based on a single administration at the time of surgery, and without any known adverse effects.Keywords
This publication has 25 references indexed in Scilit:
- Updated international clinical recommendations on scar management: part 1--evaluating the evidence.2014
- Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment.2014
- Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical TrialPlastic and Reconstructive Surgery, 2011
- Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia‐reperfusion injuryWound Repair and Regeneration, 2011
- Matrix Therapy with RGTA OTR4120 Improves Healing Time and Quality in Hairless Rats with Deep Second-Degree BurnsPlastic and Reconstructive Surgery, 2011
- Premières applications de la thérapie matricielle en chirurgie plastique et esthétiqueAnnales de Chirurgie Plastique Esthétique, 2010
- Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120Wound Repair and Regeneration, 2009
- Cutaneous Scarring: A Clinical ReviewDermatology Research and Practice, 2009
- RGTA OTR 4120, a heparan sulfate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full‐thickness excisional woundsWound Repair and Regeneration, 2008
- RGTA OTR4120, a heparan sulfate mimetic, is a possible long‐term active agent to heal burned skinJournal of Biomedical Materials Research Part A, 2006